The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.

We have made great strides in the medical community, with people having access to life-saving physical drugs as well as ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

Q4 2024 Earnings Call Transcript January 22, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.04, ...

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...

Vaccines, antibiotics, antiviral medications and anti-inflammatory drugs are all associated with a reduced risk of dementia, researchers reported in a study published Tuesday in the journal ...

Overall, women with MS have a 26% increased risk of mental illness during pregnancy and a 33% increased risk after giving birth, compared to women without the degenerative nerve disease.

A large study of 30,000 adults diagnosed with ADHD in the U.K. found women with ADHD died roughly nine years younger than women without a diagnosis. Men had about a seven-year shorter lifespan.